ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral resection of bladder tumor followed by chemoradiation for bladder preservation) as an alternative to radical cystectomy and provide guidance on the use of radiation therapy after surgery and for patients with metastatic or symptomatic disease. The guideline, ASTRO’s first focused specifically on radiation therapy across bladder cancer care, was published by Ballas et al in Practical Radiation Oncology.
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including triple oral metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from India who reported results with the novel regimen at the 2026 ASCO Annual Meeting.1
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided statistically significant prognostic information and improved risk discrimination beyond clinicopathologic variables alone in patients with early-stage triple-negative breast cancer.
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas.
AI’s Evolving Role in Clinical Care Enterprise-Wide
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland Clinic executive leaders.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
From Results to Action: Leveraging Multidisciplinary Teams to Optimize NSCLC CareMore Top Stories
Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
On September 24, the U.S. Food and Drug Administration (FDA) approved the HIF-2α inhibitor belzutifan (Welireg) in combination with the tyrosine kinase inhibitor lenvatinib (Lenvima) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with a PD-1 or ...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
A multi-cancer early detection test named Galleri from the health-care company GRAIL received a favorable vote from the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee. The Committee voted for approval of the premarket...
Guideline Update Recommends Tailoring Breast Cancer Surveillance Based on Recurrence Risk
ASCO has published a guideline update offering clinicians new recommendations for breast cancer follow-up and surveillance after primary treatment.1 For this patient population, determining the optimal frequency and timing of visits can be a challenge, according to Expert Panel Co-Chair Maryam...
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
